Gene therapy is an experimental technique that encompasses the replacement of mutated genes with healthy genes. During the treatment of cancer, the genes are replaced to fight against carcinogenic tumor cells. Gene therapy is considered to be an effective treatment for chronic diseases as they cause minimum side effects with maximum efficacy. The global cancer gene therapy market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023.
The rise in prevalence of cancer, benefits of cancer gene therapy over conventional cancer therapies, and the advancement in this field are the major factors that drive the market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in biotechnological funding encourage the R&D activities for cancer gene therapy and thus fuel the growth of the cancer gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market growth.
The global cancer gene therapy market is segmented based on therapy, end user, and geography. Based on therapy, it is categorized into gene induced immunotherapy (delivery of cytokines gene and delivery of tumor antigen gene), oncolytic virotherapy (adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others), and gene transfer (naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun). Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
KEY PLAYERS PROFILED
KEY MARKET SEGMENTS
By End User
The other players of the cancer gene therapy market include (companies not profiled in the report):
Fertility Services Market by Procedure (IVF with ICSI, Surrogacy, IVF without ICSI, IUI, and Others), Service (Fresh Non-Donor, Frozen Non-Donor, Egg and Embryo Banking, Fresh Donor, and Frozen Donor), and End User (Fertility Clinics, Hospitals, Surgical Centers, and Clinical Research Institutes) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Fertility services are treatments, which aid in treating infertility in patients. In vitro fertilization (IVF), surrogacy, artificial insemination, and others are different forms of infertility services, which assists couples with infertility problems, single mothers, and the LGBT community to procreate. The global fertility services market was valued at $16,761 million ...
February 2018 | $5370 |View Details>>
Embolization Particle or embolisation refers to the passage and lodging of an embolus within the bloodstream. It may be pathological (in which sense it is also called embolism), for example a pulmonary embolism, or therapeutic, as a hemostatic treatment for bleeding or as a treatment for some types of cancer ...
February 2018 | $4880 |View Details>>
This report studies the IV Flush Syringe market. Health care professionals use IV flush syringes to clear out patients’ catheters and intravenous lines to ensure the tubes are sterile. Nurse Assist, a Texas-based medical device manufacturer, recalled all of its Normal Saline IV Flush Syringes in 2016 after ...
February 2018 | $4880 |View Details>>
Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have ...
February 2018 | $3480 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2018 © Copyright Big Market Research